STOCK TITAN

Gritstone bio, Inc. - GRTS STOCK NEWS

Welcome to our dedicated page for Gritstone bio news (Ticker: GRTS), a resource for investors and traders seeking the latest updates and insights on Gritstone bio stock.

Gritstone bio, Inc. (Nasdaq: GRTS) is a clinical-stage biotechnology leader developing novel immunotherapies and vaccines for cancer and infectious diseases. This dedicated news hub provides investors and researchers with essential updates on the company’s pioneering work in neoantigen-targeting platforms and self-amplifying mRNA technology.

Access real-time announcements including clinical trial results, regulatory milestones, and strategic collaborations. Our curated collection features:

• Clinical development updates for GRANITE and SLATE vaccine programs
• Technology innovations in AI-driven EDGE platform and samRNA vectors
• Partnership announcements with leading research institutions
• Peer-reviewed data publications and conference presentations

Bookmark this page for streamlined tracking of Gritstone bio’s progress in advancing personalized cancer vaccines and next-generation infectious disease solutions. All content is sourced directly from company filings and verified industry channels.

Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) announced results from its SLATE v1 neoantigen immunotherapy, showing molecular responses in patients with NSCLC who previously failed immunotherapy. SLATE v1 demonstrated efficacy, with significant ctDNA decreases and an unconfirmed RECIST response. The company has initiated Phase 2 testing of SLATE v2, optimized for KRAS neoantigens, aiming to enhance immune responses. The v2 trial will enroll 60 patients with KRAS-driven tumors, receiving combined therapies with nivolumab and ipilimumab. Initial data is expected by mid-2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.07%
Tags
-
Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) announced promising data from its GRANITE individualized immunotherapy, which showed a 44% molecular response rate in advanced colorectal cancer (CRC) patients with 'cold' tumors. The Phase 1/2 study revealed that patients who achieved molecular response had a median overall survival of >17 months, significantly longer than the 7.8 months for those without. Gritstone plans to start Phase 2/3 trials in 1H 2022, aiming for FDA registration. The company highlights a favorable safety profile and robust T-cell response, indicating potential for significant clinical advancements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.07%
Tags
-
Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) announced a $55 million private investment in public equity (PIPE) financing by selling 5 million shares at $11.00 each. The financing, led by Frazier Life Sciences Public Fund, aims to support the company's growth in immunotherapy and vaccine development, particularly for infectious diseases. The closing is expected by September 17, 2021, subject to customary conditions. Gritstone has committed to filing a registration statement for the resale of these shares. The company develops next-gen immunotherapies through its proprietary Gritstone EDGE™ platform.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-15.07%
Tags
none
Rhea-AI Summary

Gritstone bio, a clinical-stage biotechnology company, announced a data update webcast on September 17, 2021, during the ESMO Annual Meeting. This event will focus on the Phase 1/2 data from its GRANITE immunotherapy program for advanced solid tumors, along with data from the SLATE shared neoantigen immunotherapy program targeting KRAS mutations. Presenters include Dr. Andrew Allen, Dr. Daniel Catenacci, and Dr. Thierry Andre. Registration for the webcast is available on Gritstone's website, with a replay accessible the following day.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.93%
Tags
conferences
-
Rhea-AI Summary

Gritstone bio (Nasdaq: GRTS), a clinical-stage biotech firm, announced its participation in two investor conferences this September. The H.C. Wainwright 23rd Annual Global Investment Conference is scheduled for September 13, 2021, at 7:00 a.m. ET, featuring a presentation by CEO Andrew Allen. The Cantor Virtual Global Healthcare Conference will follow on September 29, 2021, at 2:40 p.m. ET, with CFO Celia Economides presenting. The webcasts will be accessible on the company's website and archived for 30 days.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.8%
Tags
none
-
Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) has secured funding of up to $20.6 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance its CORAL COVID-19 vaccine program. This funding will support a Phase 1 clinical trial in South Africa, focusing on a second-generation vaccine utilizing self-amplifying mRNA technology to elicit a robust immune response against SARS-CoV-2 variants. The study aims to optimize dosing and antigenic content across diverse populations, including the elderly and immunocompromised.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.5%
Tags
covid-19
Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) announced the granting of nonqualified stock options to eight employees, totaling 240,250 shares, at an exercise price of $7.29, equal to the closing stock price on August 11, 2021. These grants are part of an inducement for new hires and will vest over four years. The company is advancing immunotherapy programs for cancer and infectious diseases, including an individualized neoantigen-based treatment and a second-generation COVID-19 vaccine. The press release also includes forward-looking statements about ongoing clinical trials and potential risks involved.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.5%
Tags
none
-
Rhea-AI Summary

Gritstone bio, Inc. (Nasdaq: GRTS) will host a KOL webinar on its colorectal cancer neoantigen programs on August 18, 2021, at 11 AM ET. KOL Michael J. Overman, M.D. from MD Anderson will present the unmet needs in colorectal cancer treatment and the role of ctDNA. CEO Dr. Andrew Allen will discuss how Gritstone's immunotherapy approach targets tumor-specific neoantigens and will preview data from the Phase 1/2 GRANITE trial, which has completed patient enrollment. Key findings will be presented at the upcoming European Society of Medical Oncology (ESMO) conference in September.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.39%
Tags
conferences
-
Rhea-AI Summary

Gritstone bio reported significant developments in its clinical-stage programs and financial results for Q2 2021. The company has completed enrollment in its Phase 2 expansion cohorts of the GRANITE trial for advanced solid tumors. Financially, Gritstone held $176.2 million in cash and equivalents as of June 30, 2021, up from $172.1 million at the end of 2020. Research and development expenses rose to $22.1 million due to increased personnel costs. Collaboration revenue surged to $2.8 million, driven by a partnership with Gilead, compared to $0.5 million in Q2 2020.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.29%
Tags
Rhea-AI Summary

On July 15, 2021, Gritstone bio (Nasdaq: GRTS) announced the grant of nonqualified stock options to five employees, totaling 77,800 shares at an exercise price of $8.77, effective July 12, 2021. Additionally, the new CFO, Celia Economides, received options for 215,000 shares at $9.76, based on a June 23, 2021 closing price. These stock options vest over four years, starting with 25% on the first anniversary. This grant aligns with Nasdaq regulations and aims to incentivize employee retention, crucial for Gritstone's ongoing immunotherapy developments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.79%
Tags
none
Gritstone bio, Inc.

Nasdaq:GRTS

GRTS Rankings

GRTS Stock Data

3.80M
118.11M
1.91%
29.03%
6.37%
Biotechnology
Biological Products, (no Disgnostic Substances)
Link
United States
EMERYVILLE